Achieve Life Sciences, Inc.
Achieve Life Sciences, Inc. (Nasdaq: ACHV) is a late-stage clinical specialty pharmaceutical company developing cytisinicline, a nicotine-dependence treatment candidate for smoking and e-cigarette cessation. The naturally occurring alkaloid is designed to reduce cravings and withdrawal symptoms and lessen nicotine’s… From the company’s description.
In fiscal 2025, Achieve Life Sciences, Inc. reported a net loss of $54.65M. Operations used $49.47M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Achieve Life Sciences, Inc. does
In the company’s own words
Achieve Life Sciences, Inc. (Nasdaq: ACHV) is a late-stage clinical specialty pharmaceutical company developing cytisinicline, a nicotine-dependence treatment candidate for smoking and e-cigarette cessation. The naturally occurring alkaloid is designed to reduce cravings and withdrawal symptoms and lessen nicotine’s rewarding effects; it is investigational in the United States, where the company’s application for smoking cessation is under FDA review. Achieve holds an exclusive license to develop and commercialize cytisinicline outside territories served by Sopharma, which markets the Tabex brand in parts of Central and Eastern Europe and other regions. The company is also developing cytisinicline for vaping cessation, for which it has received FDA Breakthrough Therapy designation. Achieve focuses on developing and commercializing this single product candidate and reports no separate business segments. Its clinical program includes studies of six- and 12-week treatment regimens, and it has partnered with a U.S.-based manufacturer for potential commercial supply. The supplied filing text does not state a corporate website.
Company details
- Sector
- Health Care
- Industry (SIC)
- Chemicals
- Headquarters
- SEATTLE, WA
- Fiscal year end
- December
- CIK
- 949858
- SIC
- 2835
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Achieve Life Sciences, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Achieve Life Sciences, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Achieve Life Sciences, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Achieve Life Sciences, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Achieve Life Sciences, Inc.'s last four quarterly filings that the numbers alone won't show?”